New Drug Combination from Liverpool Company Shows Promise for Breaking Breast Cancer Resistance
April 27, 2015
Liverpool based drug development company, Evgen Pharma, working with researchers from The University of Manchester, have developed a new combination of drugs which could overcome treatment resistance and relapse in breast cancer.
In research revealed at the American Association of Cancer Research annual conference this week, researchers show that in the most common type of breast cancer, affecting 70 per cent of patients, the Evgen drug Sulforadex helps overcome resistance to routinely used hormonal treatments by targeting the cancer stem cell population.
The new combination therapy, combines Evgen’s Wnt pathway-suppressing drug, Sulforadex with standard hormonal treatments. This targets both the estrogen-sensitive cells and the remaining cancer stem cells at the same time.
Evgen Pharma, which is headquartered in Liverpool Science Park has received more than £1.7 million funding from The North West Fund for Biomedical, managed by SPARK Impact.
Dr Marc d’Abbadie, investment director at SPARK impact, said: “SPARK Impact is delighted to see Evgen’s continued technical progress in such a crucial area. This new combination of drugs has the potential to help thousands of women whose breast cancer is resistant to standard treatment.”
Dr David Howat, Head of Research and Development at Evgen Pharma said: “We are really excited about the data presented at the AACR. Dr Rob Clarke and his excellent research team at the University’s Institute of Cancer Sciences have demonstrated the efficacy of Sulforadex in patient derived cancer tissues in vitro and, importantly, in an in vivo setting. We now intend to extend this collaboration and advance Sulforadex into a clinical trial with breast cancer patients.”
The North West Fund for Biomedical is part of the wider North West Fund which is financed jointly by the European Regional Development Fund and the European Investment Bank.